News
CALC
1.150
0.00%
0.000
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 1d ago
Weekly Report: what happened at CALC last week (1012-1016)?
Weekly Report · 3d ago
CalciMedica Announces CFO Resignation and Leadership Transition
TipRanks · 6d ago
CalciMedica Announces Stephen Bardin To Resign As CFO Effective After Q3 2026 10-Q Filing
Benzinga · 6d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 10/15 21:05
Weekly Report: what happened at CALC last week (1005-1009)?
Weekly Report · 10/12 09:48
Weekly Report: what happened at CALC last week (0928-1002)?
Weekly Report · 10/05 09:48
CalciMedica Establishes $25 Million ATM Stock Program
TipRanks · 09/30 20:33
Weekly Report: what happened at CALC last week (0921-0925)?
Weekly Report · 09/28 09:45
Weekly Report: what happened at CALC last week (0914-0918)?
Weekly Report · 09/21 09:46
CalciMedica Regains Nasdaq Compliance, Listing Status Stabilized
TipRanks · 09/16 20:38
CalciMedica Regains Nasdaq Compliance
Benzinga · 09/16 20:05
Weekly Report: what happened at CALC last week (0907-0911)?
Weekly Report · 09/14 09:48
Weekly Report: what happened at CALC last week (0831-0904)?
Weekly Report · 09/07 09:45
CalciMedica Addresses Nasdaq Equity Compliance Amid Bid-Price Risk
TipRanks · 09/02 12:47
Weekly Report: what happened at CALC last week (0824-0828)?
Weekly Report · 08/31 09:49
CalciMedica Announces 1-for-5 Reverse Stock Split
NASDAQ · 08/27 18:13
CalciMedica announces 1-for-5 reverse stock split; shares down
Seeking Alpha · 08/27 13:28
CalciMedica to effect 1-for-5 reverse stock split
TipRanks · 08/27 13:16
*CalciMedica: Split Intended to Bring Co Into Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq Cap Market >CALC
Dow Jones · 08/27 13:01
More
Webull provides a variety of real-time CALC stock news. You can receive the latest news about CALCIMEDICA INC through multiple platforms. This information may help you make smarter investment decisions.
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).